Analysis of HER2 expression and gene amplification in adenocarcinoma of the stomach and the gastro-oesophageal junction: rationale for the Belgian way of working.

Jouret-Mourin, Anne;Hoorens, Anne;De Hertogh, Gert;Vanderveken, J;Van Cutsem, Éric;et.al.
(2012) Acta Gastro-Enterologica Belgica (Multilingual Edition) — Vol. 75, n° 1, p. 9-13 (2012)

Files

No attached file found for this publication.

Details

Authors
  • Jouret-Mourin, AnneUCLouvain
    Author
  • Hoorens, Anne
    Author
  • De Hertogh, Gert
    Author
  • Vanderveken, JUCLouvain
    Author
  • Demetter, PieterUCLouvain
    Author
  • Van Cutsem, Éric
    Author
Show more
Abstract
The Human Epidermal growth factor Receptor 2 (HER2) has been established as a key player in the development of certain human tumors. ToGA trial has demonstrated that the addition of the monoclonal antibody blocking HER2 receptor, trastuzumab (Herceptin®), to chemotherapy significantly improves overall survival of patients with HER2-positive advanced or metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. Therefore, it is essential that pathologists guarantee an accurate testing of HER2 status in these tumours. Following the international recommendations and the Belgian criteria for reimbursement of trastuzumab, a consortium of expert pathologists (Belgian Working Group Molecular Pathology) proposes an adaptation of the international guidelines in order to develop strategies for optimal performance, interpretation and reporting assays.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Jouret-Mourin, A., Hoorens, A., De Hertogh, G., Vanderveken, J., Demetter, P., & Van Cutsem, É. (2012). Analysis of HER2 expression and gene amplification in adenocarcinoma of the stomach and the gastro-oesophageal junction: rationale for the Belgian way of working. Acta Gastro-Enterologica Belgica (Multilingual Edition), 75(1), 9-13. https://hdl.handle.net/2078.5/68388 (Original work published 2012)